Phaarmasia (523620)

Score breakdown: P/E: 1/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At first glance, Phaarmasia looks like a fast-growing pharmaceutical story. Sales up 240%, profits up 216%, and a PEG of 0.11 would normally tempt me. But Graham taught me that a good price is only safe when the numbers are trustworthy. Here they are not. The market cap is ₹36 crore, and the P/E of 25.83 implies net profit of barely ₹1.4 crore. Yet the latest quarter shows sales of ₹16 crore and net profit of ₹16 crore. If that quarterly profit were real and repeatable, this stock would be absurdly cheap. If it is an exceptional item—and ROCE of -16.47% tells me operating returns are negative—then the 178.73% ROE is an artifact of a tiny book value, not proof of a wonderful business. A negative return on capital with 240% sales growth is a red flag. It suggests the company may have non-operating income masking weak core operations. The price has fallen from ₹131.75 to ₹52.62, so the market is already questioning the quality. There is no dividend, promoter holding is unavailable, and the F-score of 6/9 is okay but not strong. I cannot call this a moat. It is a fast grower on the surface, but a value investor must understand the source of earnings before paying even 26 times trailing earnings. My discipline: if the numbers don't tie, I walk away. I would watch whether operating cash flow and ROCE turn positive, and whether the ₹16 crore profit recurs next quarter. Until then, this is speculation, not investing.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer